Empiric use of Anticoagulation in Hospitalized Patients with COVID-19: A Propensity Score-Matched Study of Risks and Benefits

doi:10.21203/rs.3.rs-242205/v1

Download PDF

Research

Empiric use of Anticoagulation in Hospitalized Patients with COVID-19: A Propensity Score-Matched Study of Risks and Benefits

https://doi.org/10.21203/rs.3.rs-242205/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Background: Hospitalized patients with COVID-19 demonstrate a higher risk of developing thromboembolism. Anticoagulation (AC) has been proposed for high-risk patients, even without confirmed thromboembolism. However, benefits and risks of AC are not well assessed due to insufficient clinical data. We performed a retrospective analysis of outcomes from AC in a large population of COVID-19 patients.

Methods: We retrospectively reviewed 1189 patients hospitalized for COVID-19 between March 15 and May 15, 2020, with primary outcomes of mortality, invasive mechanical ventilation, and major bleeding. Patients who received therapeutic AC for known indications were excluded. Propensity score matching of baseline characteristics and admission parameters was performed to minimize bias between cohorts.

Results: The analysis cohort included 973 patients. Forty-four patients who received therapeutic AC for confirmed thromboembolic events and atrial fibrillation were excluded. After propensity score matching, 133 patients received empiric therapeutic AC while 215 received low dose prophylactic AC. Overall, there was no difference in the rate of invasive mechanical ventilation (73.7% versus 65.6%, p = 0.133) or mortality (60.2% versus 60.9%, p = 0.885). However, among patients requiring invasive mechanical ventilation, empiric therapeutic AC was an independent predictor of lower mortality (hazard ratio [HR] 0.476, 95% confidence interval [CI] 0.345-0.657, p < 0.001) with longer median survival (14 days vs 8 days, p < 0.001), but these associations were not observed in the overall cohort (p = 0.063). Additionally, no significant difference in mortality was found between patients receiving empiric therapeutic AC versus prophylactic AC in various subgroups with different D-dimer level cutoffs. Patients who received therapeutic AC showed a higher incidence of major bleeding (13.8% vs 3.9%, p < 0.001). Furthermore, patients with a HAS-BLED score of ≥2 had a higher risk of mortality (HR 1.482, 95% CI 1.110-1.980, p = 0.008), while those with a score of ≥3 had a higher risk of major bleeding (Odds ratio: 1.883, CI: 1.114-3.729, p = 0.016).

Conclusion: Empiric use of therapeutic AC conferred survival benefit to patients requiring invasive mechanical ventilation, but did not show benefit in non-critically ill patients hospitalized for COVID-19. Careful bleeding risk estimation should be pursued before considering escalation of AC intensity.

General Biochemistry

COVID-19

Anticoagulation (AC)

ventilation

The global pandemic of SARS-CoV-2 infection with resulting coronavirus disease 2019 (COVID-19) has resulted in worldwide devastating health crises. [1, 2]. Hemostatic abnormalities have been seen in patients with COVID-19, including elevated D-dimer levels, thrombocytopenia, increased fibrin degradation products, disseminated intravascular coagulation (DIC), and thromboembolism [1, 3-9]. The reported incidence of thromboembolic events can be 20-30% in various retrospective studies [10, 11]. Furthermore, these abnormalities were associated with higher rates of mechanical ventilation, intensive care unit (ICU) admission, and death [5].

During the early phase of the COVID-19 pandemic, and with evolving knowledge about related coagulopathies and thrombosis complications, there was a lack of consensus about appropriate anticoagulation (AC) intensity. Initially, prophylactic intensity of AC was recommended for all patients hospitalized for COVID-19 [12]. However, increasing evidence demonstrated that patients developed venous thromboembolism (VTE) despite the standard pharmacological prophylaxis, especially in critically ill patients [11, 13]. Therefore, empiric use of higher intensity therapeutic AC was proposed for patients with elevated D-dimer values, even without confirmed thromboembolism [11, 14-16]. However, safety concerns arose with evidence of increased bleeding risk in certain patients, thus there appears to be an unclear benefit with empiric therapeutic AC in COVID-19 patients with high pro-thrombotic risks [17, 18].

As New York City (NYC) became the epicenter of the COVID-19 pandemic in March 2020, our hospital in the South Bronx admitted and managed SARS-CoV-2 infections ranging from moderate to severe and critical disease. Therapeutic AC was used empirically at the discretion of the treating physicians when there was a high clinical suspicion of thrombosis or embolism with elevated D-dimers. We aimed at assessing the impact of empiric use of therapeutic AC on the outcome of a large cohort of hospitalized patients with COVID-19.

Study design and patient population

This is a retrospective cohort study conducted in a tertiary, acute care hospital in South Bronx, New York. We included all hospitalized adults with a positive SARS-CoV-2 PCR result from March 1 to May 15, 2020. Patients who were excluded from the study were those who died or were discharged within 48 hours after admission, those who were transferred to another facility, those who were on long-term AC before the admission, and those who received thrombolytics during the hospital course. Follow-up continued through July 1, 2020, when all participants had confirmed outcomes (discharged alive versus death). This work was approved by our hospital Institutional Review Board (IRB: 20-017).

Therapeutic anticoagulants included enoxaparin (1mg/kg twice daily), apixaban (≥ 5mg twice daily), unfractionated heparin (UFH) infusion, and fondaparinux (≥ 5mg once daily). The indications of empiric therapeutic AC were persistently high oxygen requirement with elevated D-dimer more than 6 times the upper limit of normal or age-adjusted D-dimer cutoff (age in years x 10mcg/L for patients over 50 years old). [19] Those who received therapeutic AC for known indications, including confirmed VTE (pulmonary embolism [PE], deep venous thrombosis [DVT]), arterial thrombotic events (acute coronary syndrome, acute ischemic stroke, and acute peripheral artery thrombosis), and atrial fibrillation, were excluded from the final analysis.

Data collection and definition of variables

Sociodemographic and broad characteristics including age, sex, ethnicity, and comorbidities (hypertension, diabetes, chronic lung disease, chronic kidney disease, congestive heart disease, chronic liver disease, cancer, HIV, transplant, and other immunosuppression conditions) and presenting symptoms were collected from medical records. The Charlson Comorbidity Index (CCI), was used as a measure of aggregate comorbidity burden [20]. Sepsis was determined by a quick SOFA score (altered mental status, respiratory rate ≥22, and/or systolic blood pressure ≤100) ≥2 on admission. [21] The severity of COVID-19 infection on admission was classified into three categories (moderate, severe, critical) according to World Health Organization (WHO) guidelines. Moderate cases were defined as hospitalized patients with any of the following: fever, cough, or shortness of breath with radiographic evidence of pulmonary infiltrates and O2 saturation >94% on room air. Severe cases were defined as hospitalized patients with respiratory rate (RR) ≥24/min, O2 saturation ≤ 94%, PaO2/FiO2 <300, and/or lung infiltrates involving >50% of lung fields within 24-48 hours. Critical cases were defined as respiratory failure requiring mechanical ventilation, shock, or organ failure [22]. Bleeding risk was evaluated by HAS-BLED score including Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use [23]. Major bleeding was defined as a fall in hemoglobin of 2 g/dL or more, requirement of 2 or more units of red blood cell transfusion, or any observed bleeding including intracranial hemorrhage, melena, hematemesis, hemoptysis, hematuria, etc. [24].

Statistical analysis

Intergroup comparison of categorical variables was performed by Pearson’s Chi-square or the Fisher Exact test. Mann-Whitney U test was used to compare nonparametric continuous variables. To reduce potential confounders, we performed propensity score matching (PSM) using a 1:2 ratio with the nearest neighbor matching procedure and a caliber of 0.3 without replacement [25]. Baseline characteristics, initial symptoms, laboratory and radiographic findings, other medications, as well as the assessment of COVID-19 severity, sepsis, and acute kidney injury, were adjusted by PSM (Table 1). Adequate matching for the major imbalance of each covariate was fully assessed by visually comparing the distribution of propensity score and standardized difference (Figure S1). Univariate and multivariate cox proportional regression models were adopted to explore predictors of survival expressed as hazard ratio (HR) and 95% confidence interval (CI). To minimize immortal bias, empiric therapeutic AC was defined as a time-dependent covariate, adjusted by time to the start of exposure. Kaplan-Meier curves were plotted for matched patients with therapeutic AC versus prophylactic AC. Logistic regression analysis was used to determine the association between AC intensity and mortality stratified by D-dimer, as well as between HAS-BLED score and risk of major bleeding. P < 0.05 was considered statistically significant. All data analysis was conducted using SPSS for Windows, version 22.0 (IBM), and R software, version 3.6.1 (R Project for Statistical Computing).

Baseline characteristics and PSM

Of the 1189 consecutive patients hospitalized with confirmed COVID-19 infection, 973 patients were included in the study. 209 (21.5%) patients received therapeutic AC and 764 (78.5%) received prophylactic AC. In the therapeutic AC group, 165 individuals empirically received full dose AC, of which 44 received higher intensity AC for specific indications (such as PE, etc., as mentioned above) and were excluded from our final analysis. A total of 28 (2.9%) thromboembolic events were confirmed including 13 incidents of acute PE, 11 occurrences of DVT, and two individuals suffered from acute ischemic strokes, and 2 experienced acute peripheral artery occlusions (Figure 1). The median duration of AC treatment was 5 days (IQR: 3-8 days). And the median time from hospital admission to the start of AC was 3 days (IQR: 0-5 days). 76.3% of patients of those treated with therapeutic AC received the first dose within 72 hours after presentation to the emergency room.

Table 1 demonstrated baseline cohort characteristics. Prior to PSM, empiric AC exposure differed between age groups, comorbidities, initial symptoms, laboratory, and radiographic findings. Patients in the therapeutic AC group had a higher prevalence of severe and critical COVID-19 and higher levels of inflammatory markers on admission. After PSM, 133 patients were included in the empiric therapeutic AC cohort while 215 patients were in the prophylactic AC cohort. All covariates were balanced between the two groups after PSM, supported by closed standard mean differences (Figure S2).

Primary outcome and risk factor analysis

Prior to PSM stratification, 83 of 133 (50.3%) patients treated with therapeutic AC died, with a median hospital stay of 11 days compared to 165 of 215 (21.6%) deaths and a median hospital stay of 7 days in patients receiving prophylactic AC. After PSM stratification, no statistical difference between the two groups was found when assessing for rates of invasive mechanical ventilation (73.7% versus 65.6%, p = 0.133) and mortality (60.2% versus 60.9%, p = 0.885). Also, the median duration of hospitalization was prolonged in patients treated with therapeutic AC (9 days versus 7 days, p < 0.001). Yet, patients receiving therapeutic AC showed a much higher risk of major bleeding (13.8% vs 3.9%, p < 0.001) (Table 1).

Among patients requiring invasive mechanical ventilation, those receiving empiric therapeutic AC showed lower mortality compared to those receiving prophylactic AC only (75.5% vs 83.7%, p < 0.001). After adjusting for baseline characteristics on admission, therapeutic AC remained an independent predictor of improved survival (adjusted hazard ratio [aHR] 0.476, 95% confidence interval [CI] 0.345-0.657, p < 0.001) among intubated patients. However, empiric therapeutic AC had no significant correlation to mortality (p = 0.063) when evaluating the entire cohort. Besides, advanced age, critical COVID-19 infection, and sepsis on admission appeared to be independent predictors of all-cause mortality regardless of invasive mechanical ventilation (Table 2). Figure 2A displayed the Kaplan-Meier survival curve for all the patients. There was no significant difference in the median survival between the two AC cohorts (p = 0.056). As indicated in Figure 2B with a Kaplan-Meier survival curve for intubated patients only, those receiving therapeutic AC had a significantly longer median survival compared to those without therapeutic AC (14 days vs 8 days, p < 0.001).

We then stratified all the patients into subgroups with various cutoffs of elevated D-dimer levels (500-7000 ng/mL). No significant difference of mortality was found between the two AC intensities in any subgroups of D-dimer scales (Table 3).

Furthermore, patients who had a HAS-BLED score of ≥2, were associated with a significantly increased risk of mortality (HR 1.482, 95% CI 1.110-1.980, p = 0.008) (Table 2). Additional analysis showed that a high HAS-BLED score (≥3) was associated with a significantly higher risk of major bleeding (incidence of major bleeding: 11.4% vs 6.1%; Odds ratio: 1.883, CI: 1.114-3.729, p = 0.016) (Table 4).

Our analysis suggested that empiric use of therapeutic AC in patients requiring invasive mechanical ventilation significantly improved survival after adjustment of age, gender, race, comorbidities, COVID-19 disease severity, and major complications. However, our results did not demonstrate any survival benefit with therapeutic AC in non-critically ill patients. Lemos et. al. reported similar results in a randomized clinical trial where the use of therapeutic intensity enoxaparin resulted in improved gas exchange over time, decreased D-dimer levels, and subsequently higher rates of successful liberation from mechanical ventilation after respiratory failure in severe COVID-19 patients [26]. In contrast, the American Society of Hematology guidelines panel suggested use of prophylactic intensity of AC over intermediate or therapeutic intensity of AC in COVID-19 related critical illness without suspected or confirmed VTE [12], but these recommendations are based on limited evidence. Still, despite widespread use of therapeutic AC, there is a current paucity of data to support empiric use in COVID-19 patients with high pro-thrombotic risk. Thus, our findings may contribute towards the ever-growing body of evidence regarding AC use in COVID-19 disease and may further contribute to therapeutic guidance.

The precise mechanistic advantage of AC remains unclear. AC was presumed to provide benefit by partially blocking thrombin formation and thus dampen the overwhelming inflammatory response following lung tissue damage in acute respiratory distress syndrome (ARDS) [27, 28]. However, post-mortem studies showed that thrombi in COVID-19 often developed as a consequence of direct vascular damage associated with viral infection and severe inflammation [17]. If so, the role of therapeutic AC in this scenario might not provide greater benefit than standard prophylactic AC, yet raises bleeding risk [18]. Yet, while the therapeutic mechanism remains unclear, our findings demonstrated that therapeutic AC provided mortality benefit to ICU patients with critical COVID-19 disease, but overall, we observed increased adverse bleeding events. Therefore, since critically ill COVID-19 patients admitted to the ICU carried higher thromboembolic risks (especially if intubated, sedated, paralyzed, and immobilized) then therapeutic AC may be reasonably considered. However, while escalating AC intensity may improve outcomes, its use should be balanced with bleeding risks on a case-to-case basis to mitigate the hemorrhagic events.

Since AC likely carries benefits, yet bring an elevated risk of adverse bleeding, D-dimer levels were initially used as a biomarker to guide appropriate use of AC therapy. Studies have demonstrated a correlation between varying levels of D-dimer (ranging from >1000 ng/ml to >2590 ng/ml) and PE or mortality in patients with COVID-19 [2, 10, 29]. Early data from Tang et. al. suggested that patients with markedly elevated D-dimer levels (>3000 ng/mL or >6-fold of upper limit normal) would likely benefit from a higher dose of AC even with a low risk of thromboembolism [14, 15]. In contrast, recent evidence recommended against using D-dimer level cutoffs as the sole criteria to guide the intensity of AC [5, 12]. Our results further demonstrated that D-dimer levels did not correlate well with improved primary outcomes with empiric therapeutic versus prophylactic AC. It is noteworthy that D-dimer is a sensitive biomarker to rule out VTE, however, it has low specificity and may be elevated due to ongoing activation of the hemostatic system with inflammation, sepsis, liver disease, etc. (all of which can all be encountered in COVID-19). As such, elevated d-dimer alone is not sufficient to guide AC intensity, rather the whole clinical scenario should be considered.

Compared to other studies, our results showed a higher frequency of major bleeding among patients receiving therapeutic AC [18, 30]. It is likely related to the fact that only the highest doses were used in our study cohort, instead of the intermediate doses seen in other similar studies [18, 30]. Interestingly, HAS-BLED scores may offer a promising tool to assess bleeding risk. This risk-assessment tool was initially developed to evaluate bleeding risk in anti-coagulated patients affected by atrial fibrillation [31], and later was applied for patients with acute VTE [32-34], acute coronary syndrome (ACS) [35, 36], intracranial hemorrhage (ICH) [37, 38], postoperative AC after cardiac and vascular interventions [39, 40], etc. A score of 0 indicates low risk, 1–2 indicates moderate risk, and ≥3 indicates high risk. Our post-hoc analysis consistently demonstrated that a higher HAS-BLED score was associated with worse outcomes, with a score of ≥3 correlated with a higher bleeding risk and a score of ≥2 associated with a higher mortality. We suggested that use of the HAS-BLED rating system may help assess for risk stratification and guide AC dose selection.

Several limitations should be noted in the present study [10, 11]. First, by nature being a single-center retrospective review, this study is limited by sample size and generalizability. Also, the decision to start therapeutic AC was at the discretion of the treating physician, hence we believe there might have been selection bias, which created a smaller untreated group of critically ill patients. We were unable to match for all critically ill patients receiving AC, so there may have been residual confounding despite our use of propensity matching methods. Finally, due to COVID-19 related logistic constraints of treating COVID-19 during a time when the hospital was under surge capacity, diagnostic imaging for VTEs especially CT scans were restricted, even for critically ill and mechanically ventilated patients [14, 15].

Our results demonstrated that the empiric use of therapeutic AC conferred survival benefit to critically ill patients requiring invasive mechanical ventilation, but had limited benefit to non-critically ill patients hospitalized for COVID-19. Given the higher risk of mortality among patients with a high HAS-BLED score, we believe that a balanced assessment of AC benefits and bleeding risks is important before considering escalation of AC intensity.

Author contributions

BY and VM designed the study. BY, VP, AC, and AP collected all the data. BY and DK performed the statistical analysis. BY drafted the manuscript. VM, DK, and GH participated in the revision of the manuscript. All authors read and approved the final manuscript.

Conflict of interests

The authors have no relevant conflicts.

Consent for publication

Written informed consent was waived due to urgent need of data collection.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of New York City Health + Hospitals/ Lincoln Medical Center (IRB: 20-017).

Availability of data and material

All data generated or analyzed during this study are included in the manuscript and the supplementary material.

Funding

None

Acknowledgement

We acknowledged all the doctors and nurses working in treatment of COVID-19 patients in New York City Health + Hospitals/ Lincoln Medical Center, the Bronx, New York, USA.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062.
Zhang S, Liu Y, Wang X, Yang L, Li H, Wang Y, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J Hematol Oncol. 2020;13(1):120.
Danwang C, Endomba FT, Nkeck JR, Wouna DLA, Robert A, Noubiap JJ. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020;8:37.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(23):2950-2973.
Mei H, Luo L, Hu Y. Thrombocytopenia and thrombosis in hospitalized patients with COVID-19. J Hematol Oncol. 2020;13(1):161.
Bao C, Tao X, Cui W, Yi B, Pan T, Young KH, et al. SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol. 2020;9:16.
Som A, Lang M, Little B. Pulmonary Vascular Pathology in Covid-19. N Engl J Med. 2020;383(9):887.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.
Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020;50(1):72-81.
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.
Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020;6(4):260-261.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-1099.
Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122-124.
Cattaneo M, Bertinato EM, Birocchi S, Brizio C, Malavolta D, Manzoni M, et al. Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified? Thromb Haemost. 2020;120(8):1230-1232.
Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost. 2020.
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. 2020;8:49.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care. 2019;23(1):374.
Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020 [https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
Meng Y, Lu W, Guo E, Liu J, Yang B, Wu P, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis. J Hematol Oncol. 2020;13(1):75.
Lemos ACB, do Espirito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359-366.
Li J, Li Y, Yang B, Wang H, Li L. Low-molecular-weight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(2):414-422.
Poterucha TJ, Libby P, Goldhaber SZ. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437-444.
Mouhat B, Besutti M, Bouiller K, Grillet F, Monnin C, Ecarnot F, et al. Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients. Eur Respir J. 2020;56(4).
Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500.
Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clin Cardiol. 2015;38(9):555-561.
Rief P, Raggam RB, Hafner F, Avian A, Hackl G, Cvirn G, et al. Calculation of HAS-BLED Score Is Useful for Early Identification of Venous Thromboembolism Patients at High Risk for Major Bleeding Events: A Prospective Outpatients Cohort Study. Semin Thromb Hemost. 2018;44(4):348-352.
Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ, et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One. 2015;10(4):e0122520.
Desai AK, Pang J, Aparnath M, Ilowite J. Utility of Inferior Vena Cava Filters in Severe Pulmonary Embolism, Catheter-directed Therapy in Massive and Submassive Pulmonary Embolism, and HAS-BLED Score to Determine Risk of Major Hemorrhage in Pulmonary Embolism. Am J Respir Crit Care Med. 2016;193(11):1301-1303.
Castini D, Persampieri S, Sabatelli L, Erba M, Ferrante G, Valli F, et al. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels. 2019;34(10):1621-1630.
Hsieh MJ, Wang CC, Chen CC, Wang CL, Wu LS, Hsieh IC. HAS-BLED score predicts risk of in-hospital major bleeding in patients with acute non-ST segment elevation myocardial infarction. Thromb Res. 2015;136(4):775-780.
Lip GY, Lin HJ, Hsu HC, Su TC, Chen MF, Lee YT, et al. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study. Int J Cardiol. 2013;168(3):1832-1836.
Chan KH, Ka-Kit Leung G, Lau KK, Liu S, Lui WM, Lau CP, et al. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg. 2014;82(1-2):e219-223.
Freixo C, Ferreira V, Goncalves J, Teixeira G, Antunes I, Veiga C, et al. HAS-BLED Score Predicts the Risk of Major Bleeding in Chronic Anticoagulation after Lower Limb Surgical Revascularization. Ann Vasc Surg. 2019;59:190-194.
Konishi H, Miyauchi K, Tsuboi S, Ogita M, Naito R, Dohi T, et al. Impact of the HAS-BLED Score on Long-Term Outcomes After Percutaneous Coronary Intervention. Am J Cardiol. 2015;116(4):527-531.

Table 1. Characteristics of all hospitalized COVID-19 patients receiving empiric therapeutic AC versus prophylactic AC.

	Prior to Propensity Score Match			After Propensity Score Match
Parameters	Therapeutic AC (n=165)	Prophylactic AC (n=764)	p value	Therapeutic AC (n=133)	Prophylactic AC (n=215)	p value
Age, median (IQR)	61 (54-72)	62 (50-75)	0.894	62 (54-72)	65 (52-75)	0.345
Age categories, n (%)			0.001*			0.064
18-39	11 (5.3)	87 (11.4)		6 (4.5)	19 (8.8)
40-59	78 (37.3)	244 (31.9)		50 (37.6)	61 (28.4)
60-79	101 (48.3)	309 (40.4)		65 (48.9)	101 (47.0)
≥80	19 (9.1)	124 (16.2)		12 (9.0)	34 (15.8)
Gender, Female, n (%)	77 (36.8)	336 (44.0)	0.064	47 (35.3)	80 (37.2)	0.725
Ethnicity, n (%)			0.348			0.737
Latinx	141 (67.5)	482 (63.0)		97 (72.9)	154 (71.6)
Black	62 (29.7)	236 (31.0)		34 (25.6)	55 (25.6)
White	4 (1.9)	29 (3.8)		2 (1.5)	6 (2.8)
Asian	2 (1.0)	17 (2.2)		0	0
Body Mass Index, median (IQR)	30.1 (26.2-35.0)	29.0 (25.0-33.7)	0.066	30.2 (26.4-35.0)	29.4 (25.0-34.2)	0.155
Body Mass Index categories, n (%)			0.136			0.258
Underweight	1 (0.6)	14 (1.8)		1 (0.8)	5 (2.3)
Normal	28 (17.0)	170 (22.3)		21 (15.8)	42 (19.1)
Overweight	49 (29.7)	244 (31.9)		39 (29.3)	74 (34.4)
Obesity	107 (51.2)	327 (42.8)		72 (54.1)	95 (44.2)
Current smoker, n (%)	4 (1.9)	36 (4.7)	0.071	1 (0.8)	3 (1.4)	1.000
Past diagnosis, n (%)
Diabetes mellitus	94 (45.0)	358 (46.9)	0.629	55 (41.4)	91 (42.3)	0.858
Hypertension	120 (57.4)	322 (42.1)	<0.001*	67 (50.4)	102 (47.4)	0.595
Chronic lung disease	34 (16.3)	148 (19.4)	0.308	24 (18.0)	39 (18.1)	0.982
Congestive heart failure	8 (3.8)	55 (7.2)	0.049*	6 (4.5)	12 (5.6)	0.661
Chronic kidney disease, stage>3	24 (11.5)	105 (13.7)	0.393	12 (9.0)	23 (10.7)	0.614
Cancer	19 (9.1)	52 (6.8)	0.260	10 (7.5)	19 (8.8)	0.665
Chronic liver disease and Cirrhosis	9 (5.5)	20 (2.6)	0.047*	6 (4.5)	10 (4.7)	0.952
HIV, transplant, and other immunosuppression status	7 (4.2)	34 (4.5)	0.906	7 (5.3)	11 (5.1)	0.952
Charlson Comorbidities Index (CCI), median (IQR)	3 (1-4)	3 (1-5)	0.909	2 (1-4)	3 (1-4)	0.976
HAS-BLED score, median (IQR)	2 (1-3)	2 (1-4)	0.061	2 (1-2)	2 (1-3)	0.109
Initial symptoms, n (%)
Fever	127 (60.8)	461 (60.3)	0.911	83 (62.4)	129 (60.0)	0.655
Cough	148 (70.8)	497 (65.1)	0.118	97 (72.9)	149 (69.3)	0.470
Dyspnea	166 (79.4)	520 (68.1)	0.001*	107 (80.5)	167 (77.7)	0.538
Gastrointestinal symptoms	33 (15.8)	205 (26.8)	0.001*	24 (18.0)	51 (23.7)	0.211
Neurologic symptoms	37 (17.7)	132 (17.3)	0.885	22 (16.5)	45 (20.9)	0.313
Initial laboratory test, median (IQR)
White blood cell count [4.8-10.8 x10³/µL]	10.0 (7.0-13.2)	7.6 (5.5-10.4)	<0.001*	9.8 (6.9-12.5)	9.0 (6.6-11.5)	0.165
Absolute lymphocyte cell count [1.0-4.8 x10³/µL]	1.0 (0.6-1.3)	1.0 (0.7-1.4)	0.027*	0.9 (0.6-1.3)	0.9 (0.7-1.3)	0.428
Absolute neutrophil cell count [1.8-7.8 x10³/µL]	8.5 (5.6-11.3)	5.7 (3.9-8.4)	<0.001*	8.4 (5.3-10.6)	7.2 (4.9-9.5)	0.077
Hemoglobin [14-18 gr/dL]	13.2 (11.9-14.3)	13.2 (11.6-14.5)	0.864	13.0 (11.6-14.1)	13.1 (11.5-14.6)	0.467
Platelet count [150-450/µL]	248.0 (194.0-312.0)	215.0 (167.0-275.0)	<0.001*	241.0 (192.5-307.5)	232.0 (177.0-310.0)	0.462
D-dimer [<=230 ng/mL]	1207.0 (413.0-5721.0)	498.0 (258.0-897.0)	<0.001*	882.0 (403.0-3278.5)	793.0 (393.0-2024.1)	0.051
Lactate dehydrogenase [135-225 U/L]	592.5 (457.0-768.8)	457.0 (333.3-640.8)	<0.001*	599.0 (459.0-724.5)	605.0 (398.0-715.0)	0.597
C-reactive protein [0-0.40 mg/dL]	19.1 (10.8-30.0)	11.3 (5.5-21.3)	<0.001*	20.7 (11.2-27.1)	18.3 (10.8-26.5)	0.368
Interleukin-6 [0-5.5 pg/mL]	129.5 (62.1-285.8)	78.3 (27.1-172.3)	<0.001*	221.7 (92.6-299.5)	238.6 (96.7-278.7)	0.249
Ferritin [12-300 ng/mL]	883.0 (492.0-1606.0)	688.0 (365.0-1224.5)	0.002*	1070.0 (502.5-1532.5)	1067.0 (562.0-1387.5)	0.568
Radiographic findings, n (%)
Bilateral patchy infiltrates	131 (62.7)	412 (53.9)	0.024*	91 (68.4)	129 (60.0)	0.137
Ground glass opacity	82 (39.2)	217 (28.4)	0.003*	53 (39.8)	70 (32.6)	0.238
Consolidation	19 (9.1)	102 (13.4)	0.098	12 (9.0)	26 (12.1)	0.207
Atelectasis	4 (1.9)	33 (4.3)	0.107	2 (1.5)	7 (3.3)	0.491
Other medications received, n (%)
Hydroxychloroquine	167 (79.9)	542 (70.9)	0.010*	105 (78.9)	165 (76.6)	0.589
Azithromycin	177 (84.7)	553 (72.4)	<0.001*	111 (83.4)	173 (80.6)	0.480
Remdesevir	15 (7.2)	1 (0.1)	<0.001*	1 (0.8)	1 (0.5)	0.555
Sarilumab/Tocilizumab	26 (12.4)	35 (4.6)	<0.001*	15 (11.3)	20 (9.4)	0.540
Convalescent plasma	22 (10.5)	6 (0.8)	<0.001*	7 (5.3)	6 (3.0)	0.122
Stress dose of steroid	55 (33.3)	74 (9.7)	<0.001*	28 (18.6)	40 (18.4)	0.756
COVID-19 severity classification on admission, n (%)			<0.001*			0.458
Moderate	21 (10.0)	378 (49.3)		13 (9.8)	32 (14.9)
Severe	83 (39.7)	209 (27.4)		47 (35.3)	80 (37.2)
Critical	105 (50.2)	177 (23.2)		73 (54.9)	103 (47.9)
Sepsis by quick SOFA on admission, n (%)	37 (22.4)	230 (30.1)	0.048*	35 (26.3)	51 (23.7)	0.586
Acute kidney injury on admission, n (%)	53 (32.1)	218 (28.5)	0.358	45 (33.8)	77 (35.8)	0.707
Hospital course (unmatched)
Invasive mechanical ventilation, n (%)	128 (77.6)	221 (28.9)	<0.001*	98 (73.7)	141 (65.6)	0.113
Major bleeding, n (%)	23 (14.1)	27 (3.5)	<0.001*	18 (13.8)	8 (3.9)	<0.001*
Days of hospitalization, median (IQR)	11 (6-21)	7 (4-12)	<0.001*	9 (6-19)	7 (5-12)	<0.001*
All-cause mortality, n (%)	83 (50.3)	165 (21.6)	<0.001*	80 (60.2)	131 (60.9)	0.885

*Significant at p < 0.05

Table 2. Cox proportional hazards model of risk factors for all-cause mortality among patients with or without receiving empiric therapeutic AC

	All matched patients					Patients requiring invasive mechanical ventilation
	Death/N at risk (%)	Univariate analysis		Multivariate analysis		Death/N at risk (%)	Univariate analysis		Multivariate analysis
	Death/N at risk (%)	HR (95% CI)	p value	HR (95% CI)	p value	Death/N at risk (%)	HR (95% CI)	p value	HR (95% CI)	p value
Empiric therapeutic AC
No	131/215 (60.9)	Reference				118/141 (83.7)	Reference		Reference
Yes	80/133 (60.2)	0.792 (0.619-1.013)	0.063			74/98 (75.5)	0.536 (0.413-0.695)	<0.001*	0.476 (0.345-0.657)	<0.001*
Age
<65 years old	103/199 (51.8)	Reference		Reference		98/138 (71.0)	Reference		Reference
≥65 years old	108/149 (72.5)	1.423 (1.190-1.701)	<0.001*	1.028 (1.014-1.142)	<0.001*	90/101 (89.1)	1.276 (1.042-1.563)	0.008*	1.207 (1.006-1.526)	0.015*
Gender
Male	133/221 (60.2)	Reference				119/151 (78.8)	Reference
Female	78/127 (61.4)	0.915 (0.692-1.211)	0.536			73/88 (83.0)	0.920 (0.687-1.232)	0.577
Ethnicity
Non-Latinx	56/97 (57.7)	Reference				51/64 (79.7)	Reference
Latinx	155/251 (61.8)	0.930 (0.709-1.221)	0.603			141/175 (80.6)	1.082 (0.806-1.453)	0.598
Body-mass index
<30	104/181 (57.4)	Reference				87/111 (78.4)	Reference
≥30	107/167 (64.1)	1.011 (0.995-1.027)	0.188			105/128 (82.0)	1.002 (0.986-1.018)	0.818
Comorbidities
Diabetes mellitus	91/146 (62.3)	1.087 (0.828-1.428)	0.548			81/102 (79.4)	0.996 (0.748-1.326)	0.975
Hypertension	105/168 (62.1)	1.126 (0.860-1.475)	0.389			89/106 (84.0)	1.214 (0.914-1.613)	0.180
COPD/asthma	45/63 (71.4)	1.429 (1.028-1.988)	0.034*			45/50 (90.0)	1.502 (1.074-2.101)	0.017*
Congestive heart failure	11/18 (61.1)	1.196 (0.652-2.195)	0.564			10/11 (90.9)	1.196 (1.067-3.846)	0.031*
Chronic kidney disease	23/35 (65.7)	1.196 (0.775-1.843)	0.419			17/22 (77.3)	0.899 (0.547-1.480)	0.676
Cancer	21/29 (72.4)	1.341 (0.854-2.106)	0.202			16/19 (84.2)	1.000 (0.599-1.668)	1.000
CCI
<2	66/120 (55.0)	Reference				65/84 (77.4)	Reference
≥2	145/228 (63.6)	1.469 (1.000-2.799)	0.050			127/155 (81.9)	1.411 (0.908-2.931)	0.091
COVID-19 severity
Moderate	8/45 (17.8)	Reference		Reference		4/9 (44.4)	Reference		Reference
Severe	61/127 (48.0)	2.282 (1.091-4,771)	0.028*	2.319 (1.092-4.924)	0.029*	45/61 (73.7)	2.442 (0.882-6.765)	0.086
Critical	142 /176 (80.7)	3.242 (1.588-6.620)	0.001*	3.537 (1.706-7.330)	0.001*	143/169 (84.6)	2.810 (1.011-6.921)	0.033*	2.120 (1.004-6.715)	0.025*
Sepsis
No	143/262 (54.6)	Reference		Reference		130/170 (76.5)	Reference		Reference
Yes	68/86 (79.1)	2.456 (1.675-3.602)	<0.001*	1.354 (1.005-1.795)	0.043*	62/69 (89.9)	1.531 (1.160-2.764)	0.012*	1.414 (1.012-2.705)	0.032*
Acute kidney injury
No	128/226 (56.6)	Reference				117/152 (77.0)	Reference
Yes	83/122 (68.0)	1.367 (1.037-1.802)	0.027*			75/87 (86.2)	1.463 (0.952-2.247)	0.083
HAS-BLED score
≥1 vs <1	190/307 (61.9) vs 21/41 (51.2)	1.267 (0.942-1.693)	0.119			171/212 (80.7) vs 21/27 (77.8)	1.203 (0.762-1.898)	0.427
≥2 vs <2	143/218 (65.9) vs 68/130 (52.3)	1.482 (1.110-1.980)	0.008*			125/153 (81.7) vs 67/86 (77.9)	1.250 (0.928-1.684)	0.141
≥3 vs <3	65/88 (73.9) vs 146/260 (56.2)	1.368 (1.032-1.952)	0.015*			59/70 (84.3) vs 133/169 (78.7)	1.128 (0.829-1.535)	0.443

AC: anticoagulation; CCI: Charlson Comorbidity Index; CI: confidence interval; COPD: chronic obstructive pulmonary disease; COVID-19: coronavirus disease 2019; HAS-BLED: Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile International Normalized Ratio (INR), Elderly, Drugs or alcohol use; HR: hazard ratio.

*Significant at p < 0.05

Table 3. The association between empiric therapeutic AC and mortality of patients with COVID-19 based on the D-dimer level

D-Dimer level (ng/mL)	N. of death/N. at risk (%)			Univariate analysis
D-Dimer level (ng/mL)	Total	Therapeutic AC	Prophylactic AC	OR (95% CI)	p value
≥500	150/230 (65.2)	57/92 (62.0)	93/138 (67.4)	0.788 (0.454-1.367)	0.397
≥1000	89/134 (66.4)	39/63 (61.9)	50/71 (70.4)	0.683 (0.332-1.402)	0.297
≥2000	65/103 (63.1)	29/49 (59.2)	36/54 (66.7)	0.725 (0.325-1.618)	0.432
≥3000	52/80 (65.0)	23/36 (63.9)	29/44 (65.9)	0.915 (0.364-2.302)	0.851
≥4000	37/59 (62.7)	16/29 (55.2)	21/30 (70.0)	0.527 (0.181-1.538)	0.239
≥5000	34/50 (68.0)	16/26 (61.5)	18/24 (75.0)	0.533 (0.158-1.799)	0.308
≥6000	30/44 (68.2)	13/21 (61.9)	17/23 (73.9)	0.574 (0.159-2.066)	0.393
≥7000	26/39 (66.7)	11/19 (57.9)	15/20 (75.0)	0.458 (0.117-1.789)	0.257

OR: Odds ratio; CI: confidence interval; *Significant at p < 0.05

Table 4. The association between HAS-BLED score and major bleeding

HAS-BLED score cutoff	Major bleeding/N. at risk (%)		Univariate analysis
HAS-BLED score cutoff	≥ cutoff	<cutoff	OR (95%CI)	p value
1	23/307 (7.5)	3/41 (7.3)	1.046 (0.624-1.714)	0.488
2	12/130 (9.2)	14/218 (6.4)	1.256 (0.832-2.114)	0.103
3	10/88 (11.4)	16/260 (6.1)	1.883 (1.114-3.729)	0.016*
4	6/30 (20.0)	20/318 (9.2)	2.112 (1.152-4.421)	0.001*

OR: Odds ratio; CI: confidence interval; *Significant at p < 0.05

supplementarymaterials.docx

Download PDF

Editorial decision: Minor revision
01 Mar, 2021
Review #2 received at journal
27 Feb, 2021
Review #1 received at journal
26 Feb, 2021
Reviewer #2 agreed at journal
25 Feb, 2021
Reviewers invited by journal
25 Feb, 2021
Reviews received at journal
25 Feb, 2021
Reviewer #1 agreed at journal
25 Feb, 2021
Editor assigned by journal
18 Feb, 2021
Submission checks completed at journal
18 Feb, 2021
Editor invited by journal
18 Feb, 2021
First submitted to journal
14 Feb, 2021

You are reading this latest preprint version

Empiric use of Anticoagulation in Hospitalized Patients with COVID-19: A Propensity Score-Matched Study of Risks and Benefits

Status:

Version 1

Abstract

Figures

Introduction

Methods

Results

Discussion

Conclusions

Declarations

References

Tables

Supplementary Files

Status:

Version 1